The Metformin Aneurysm Trial (MAT)

An investigator initiated and conducted, multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial to determine the effect of metformin on abdominal aortic aneurysm (AAA) associated events, including AAA repair and AAA mortality (due to aneurysm rupture).

You may be eligible if you:

  • have an abdominal aortic aneurysm
  • are aged between 18 – 79 years old
  • are not taking metformin

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity

You are eligible if you:

  • are overweight (BMI>27kg/m2)
  • do not have diabetes
  • have established cardiovascular disease (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) OR can answer yes to two of the following:
    • are a current smoker
    • have high cholesterol
    • have high blood pressure
    • have kidney disease
    • have prediabetes

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants with Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

You are eligible if you:

  • have a BMI of 27 kg/m2
    or more
  • are aged 45 years or older
  • have heart disease
  • have kidney disease
  • have type 2 diabetes or not, and your HbA1c
    levels are less than 10 percent.

TRIUMPH-OUTCOMES

An Open-Label Biomarker Study of BHV-1300 in Graves’ Disease

You are eligible if you are:

  •  >18 years old and <75 years of age
  • Within normal weight (BMI 18-32 kg/m2)
  • Up to date with recommended immunizations
  • Have diagnosis of Graves’ disease
  • Are taking antithyroid drug as treatment

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a)

You are eligible if you are:

  • >18 years of age or older with established Atherosclerotic Cardiovascular Disease (ASCVD) , with an event or revascularization ≥ 60 days. Examples of ASCVD include:
    • heart attack,
    • bypass grafting,
    • angioplasty,
    • Ischaemic stroke,
    • carotid stenting,
    • amputation,
    • peripheral revascularisation, &
    • surgical revascularisation.
  • >18 years of age or older who are at risk for a first cardiovascular event (e.g. type 2 diabetes and high blood pressure)

A Multicenter Randomized, Double-blind, Sham-controlled Study Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy  in Individuals with Type 2 Diabetes (ReCET Study)

You are eligible if you are:

  • 22-70 years of age, inclusive
  • Type 2 diabetes
  •  HbA1C of 7.5-10.5%, inclusive
  •  BMI 27-40 kg/m2, inclusive
  • Agree not to donate blood during the study
  • Stable weight for at least 12 weeks